TITLE

FDA actions

PUB. DATE
April 2011
SOURCE
Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.
ACCESSION #
61017594

 

Related Articles

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age.  // Clinical Infectious Diseases;6/1/2011, Vol. 52 Issue 11, preceding p1343 

    The article reports that the U.S. Food and Drug Administration has approved the use of Zostavax vaccine, for the prevention of Shingles in individuals aged between 50 to 59 years in the U.S., also, Zostavax is a live attenuated virus vaccine and was already used in individuals aged above 60 years.

  • CancerVax Treatment Goes Skin Deep. Webb, Marion // San Diego Business Journal;5/19/2003, Vol. 24 Issue 20, p1 

    Assesses the efficacy of Canvaxin drug in treating patients with melanoma disease. Approval of the U.S. Food and Administration on the distribution of the vaccine in the market; Risks of side effects; Forms of skin cancer.

  • Vemurafenib Tablets (Zelborafâ„¢). Elliott, William T. // Internal Medicine Alert;10/29/2011, Vol. 33 Issue 20, p157 

    An abstract related to the U.S. Food and Drug Administration (FDA) review report conducted on the effectiveness of vemurafenib in patients with melanoma whose tumor expresses a gene mutation called BRAF V600E, is presented.

  • FDA approves Tafinlar, Mekinist for treatment of metastatic melanoma.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p26 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of dabrafenib and trametinib for treatment of melanoma patients.

  • Merck gets key approval on melanoma drug. Strauss, Eric // njbiz;9/15/2014, Vol. 27 Issue 37, p3 

    The article reports that the U.S. Food and Drug Administration has approved drug manufacturer Merck's Keytruda (pembrolizumab) drug as treatment for patients with certain types of advanced melanoma as of mid-September 2014.

  • REMS accompanies launch of new melanoma drug.  // Reactions Weekly;4/16/2011, Issue 1347, p4 

    The article reports on the approval of Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA) on March 26, 2011 for the treatment of unresectable or metastatic melanoma and the launching of a Risk Evaluation and Mitigation Strategy (REMS) by the drug's developer Bristol-Myers Squibb...

  • FDA panel nixes interferon indication. Reiman, Patty // Dermatology Times;Jan2000, Vol. 21 Issue 1, p13 

    Focuses on the United States Food and Drug Administration's Oncologic Drugs Advisory Committee's rejection of interferon type Roferon-A for treatment of surgically resected malignant melanoma. Absence of survival advantage in the study; Exclusion of some patients from the trial.

  • Breakthrough Melanoma Drug OK'd.  // Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p49 

    The article reports on the approval of Zelboraf which is the first drug that treats advanced melanoma by targeting specific gene mutation by the Food and Drug Administration (FDA) in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics